Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

173 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro.
Egan JE, Quadrini KJ, Santiago-Schwarz F, Hadden JW, Brandwein HJ, Signorelli KL. Egan JE, et al. Among authors: hadden jw. J Immunother. 2007 Sep;30(6):624-33. doi: 10.1097/CJI.0b013e3180691593. J Immunother. 2007. PMID: 17667526
A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma.
Whiteside TL, Butterfield LH, Naylor PH, Egan JE, Hadden JW, Baltzer L, Wolf GT, Berinstein NL. Whiteside TL, et al. Among authors: hadden jw. Cancer Immunol Immunother. 2012 Jun;61(6):783-8. doi: 10.1007/s00262-011-1136-x. Epub 2011 Nov 23. Cancer Immunol Immunother. 2012. PMID: 22109700 Free PMC article. Clinical Trial.
Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic.
Czystowska M, Szczepanski MJ, Szajnik M, Quadrini K, Brandwein H, Hadden JW, Whiteside TL. Czystowska M, et al. Among authors: hadden jw. Cancer Immunol Immunother. 2011 Apr;60(4):495-506. doi: 10.1007/s00262-010-0951-9. Epub 2010 Dec 23. Cancer Immunol Immunother. 2011. PMID: 21181158 Free PMC article.
Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.
Berinstein NL, Wolf GT, Naylor PH, Baltzer L, Egan JE, Brandwein HJ, Whiteside TL, Goldstein LC, El-Naggar A, Badoual C, Fridman WH, White JM, Hadden JW. Berinstein NL, et al. Among authors: hadden jw. Cancer Immunol Immunother. 2012 Jun;61(6):771-82. doi: 10.1007/s00262-011-1134-z. Epub 2011 Nov 6. Cancer Immunol Immunother. 2012. PMID: 22057678 Free PMC article. Clinical Trial.
T cell targeted immune enhancement yields effective T cell adjuvants.
Naylor PH, Hadden JW. Naylor PH, et al. Among authors: hadden jw. Int Immunopharmacol. 2003 Aug;3(8):1205-15. doi: 10.1016/S1567-5769(03)00025-0. Int Immunopharmacol. 2003. PMID: 12860176 Review.
IRX-2 increases the T cell-specific immune response to protein/peptide vaccines.
Naylor PH, Hernandez KE, Nixon AE, Brandwein HJ, Haas GP, Wang CY, Hadden JW. Naylor PH, et al. Among authors: hadden jw. Vaccine. 2010 Oct 8;28(43):7054-62. doi: 10.1016/j.vaccine.2010.08.014. Epub 2010 Aug 13. Vaccine. 2010. PMID: 20708999
A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck.
Freeman SM, Franco JL, Kenady DE, Baltzer L, Roth Z, Brandwein HJ, Hadden JW. Freeman SM, et al. Among authors: hadden jw. Am J Clin Oncol. 2011 Apr;34(2):173-8. doi: 10.1097/COC.0b013e3181dbb9d8. Am J Clin Oncol. 2011. PMID: 20539208 Clinical Trial.
Preclinical studies with IRX-2 and thymosin alpha1 in combination therapy.
Naylor PH, Hadden JW. Naylor PH, et al. Among authors: hadden jw. Ann N Y Acad Sci. 2010 Apr;1194:162-8. doi: 10.1111/j.1749-6632.2010.05475.x. Ann N Y Acad Sci. 2010. PMID: 20536465 Review.
Immunopharmacology of thymosin alpha1 and cytokine synergy.
Naylor PH, Quadrini K, Garaci E, Rasi G, Hadden JW. Naylor PH, et al. Among authors: hadden jw. Ann N Y Acad Sci. 2007 Sep;1112:235-44. doi: 10.1196/annals.1415.036. Epub 2007 Jun 13. Ann N Y Acad Sci. 2007. PMID: 17567942
IRX-2 and thymosin alpha1 (Zadaxin) increase T lymphocytes in T lymphocytopenic mice and humans.
Hadden JW, Verastegui E, Hadden E. Hadden JW, et al. Ann N Y Acad Sci. 2007 Sep;1112:245-55. doi: 10.1196/annals.1415.032. Epub 2007 Jun 28. Ann N Y Acad Sci. 2007. PMID: 17600288
173 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback